Oncology Institute, Inc. (TOI)

The Oncology Institute, Inc. (TOI) stock has experienced notable movements and events in the past six months, including a 900% rise in six months by May 2025, and a year-to-date growth of over 1200% by August 2025. As of October 27, 2025, the stock price was $4.61, having risen by 16.71% over the preceding two weeks. Key events impacting the stock include strong Q1 and Q2 2025 financial results, partnerships and expansions such as the launch of the Florida Oncology Network and a partnership with Protocol Behavioral Health, insider activity showing more stock sales than purchases, and a "Moderate Buy" analyst sentiment with an average price target of $7.00.

There is no specific information available regarding demand seasonality for The Oncology Institute, Inc.'s products and services. Demand for oncology services is generally considered to be less susceptible to seasonal fluctuations compared to other industries.

The Oncology Institute, Inc. (TOI) is a value-based oncology company that manages community-based oncology practices. Its core business revolves around delivering comprehensive cancer care services, aiming to improve patient outcomes while reducing costs through an integrated care model. The company's major products and services are categorized into Patient Services, which include physician services, in-house infusion, radiation therapy, outpatient blood product transfusions, outpatient stem cell transplants, 24/7 patient support, educational seminars, support groups, and counseling services; Dispensary, which involves in-house pharmacy services; and Clinical Trials & Other, through TOI Clinical Research, LLC (TCR), the company provides and manages clinical trial services and research for cancer patients.

The Oncology Institute, Inc. has a significant regional presence across the United States, operating approximately 70 to 86 clinic locations across five states: California, Arizona, Nevada, Florida, and Oregon. In 2024, its network reached a total of 1.9 million patients. The company also provides management services to over 14 clinic locations owned by independent oncology practices.

In the past year, The Oncology Institute, Inc. has primarily experienced positive developments and strategic growth, including new partnerships and the launch of new networks and centers of excellence. TOI has also reported achieving significant Medicare savings through its participation in the CMS Enhancing Oncology Model. There is no readily available information indicating any significant negative events, controversies, or issues that have adversely affected the company's brand reputation.

The ownership structure of The Oncology Institute, Inc. (TOI) is a mix of institutional, retail, and individual investors. As of October 2025, 141 institutional owners and shareholders have filed 13D/G or 13F forms, holding a total of 34,614,018 shares. Individual investors collectively hold a significant portion of the company, with insider ownership standing at 41.95% of outstanding equity as of October 18, 2025.